Metallothioneins and Cancer

Author(s): Tomas Eckschlager, Vojtech Adam, Jan Hrabeta, Katarina Figova, Rene Kizek.

Journal Name: Current Protein & Peptide Science

Volume 10 , Issue 4 , 2009

Become EABM
Become Reviewer

Abstract:

Metallothioneins (MTs) are low molecular, cysteine-rich proteins that have naturally-occurring Zn2+ in both clusters. They may serve as a reservoir of metals for synthesis of apoenzymes and zinc-finger transcription regulators. MTs are also involved with several important proteins e.g. p53, NF-κB, PKCl, and GTPase Rab3A. New biological roles for these proteins have been identified including those needed in the carcinogenic process. However, their use as a predictive marker remains controversial. Several reports have disclosed MTs expression as a prognostic factor for tumor progression and drug resistance in a variety of malignancies particularly breast, prostatic, ovarial, head and neck, non-small cell lung cancer, melanoma, and soft tissue sarcoma. The role of MTs as a tumor disease marker or as a cause of resistance in cancer treatment is reviewed and discussed. Moreover, we describe some analytical methods that were developed to detect MTs.

Keywords: Metallothioneins, cancer marker, cancer cell chemoresistance, detection

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 10
ISSUE: 4
Year: 2009
Page: [360 - 375]
Pages: 16
DOI: 10.2174/138920309788922243
Price: $58

Article Metrics

PDF: 17